1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 40 pages

Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014’, provides an overview of the Taisho Pharmaceutical Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Taisho Pharmaceutical Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Taisho Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Taisho Pharmaceutical Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Taisho Pharmaceutical Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate Taisho Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Taisho Pharmaceutical Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Taisho Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Taisho Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Taisho Pharmaceutical Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Taisho Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Taisho Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014
Table of Contents

Taisho Pharmaceutical Co., Ltd. Snapshot 5
Taisho Pharmaceutical Co., Ltd. Overview 5
Key Information 5
Key Facts 5
Taisho Pharmaceutical Co., Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Taisho Pharmaceutical Co., Ltd. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Taisho Pharmaceutical Co., Ltd. - Pipeline Products Glance 13
Taisho Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Taisho Pharmaceutical Co., Ltd. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Taisho Pharmaceutical Co., Ltd. - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
Taisho Pharmaceutical Co., Ltd. - Drug Profiles 18
TS-091 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
luseogliflozin 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
TS-111 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
TS-121 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
MGS-0028 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Small Molecules to Inhibit 50S RNA for Bacterial Infections 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
TASP-0415914 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
TKM-0150 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
TASP-0376377 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Taisho Pharmaceutical Co., Ltd. - Pipeline Analysis 29
Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Target 29
Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration 31
Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type 32
Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action 33
Taisho Pharmaceutical Co., Ltd. - Recent Pipeline Updates 34
Taisho Pharmaceutical Co., Ltd. - Dormant Projects 35
Taisho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products 36
Discontinued Pipeline Product Profiles 36
EPI-2010 36
TS-033 36
parogrelil 36
TS-022 36
Taisho Pharmaceutical Co., Ltd. - Locations And Subsidiaries 37
Head Office 37
Other Locations and Subsidiaries 37
Appendix 39
Methodology 39
Coverage 39
Secondary Research 39
Primary Research 39
Expert Panel Validation 39
Contact Us 40
Disclaimer 40

List of Tables

Taisho Pharmaceutical Co., Ltd., Key Information 5
Taisho Pharmaceutical Co., Ltd., Key Facts 5
Taisho Pharmaceutical Co., Ltd. - Pipeline by Indication, 2014 8
Taisho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 9
Taisho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 10
Taisho Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2014 11
Taisho Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12
Taisho Pharmaceutical Co., Ltd. - Phase II, 2014 13
Taisho Pharmaceutical Co., Ltd. - Phase I, 2014 14
Taisho Pharmaceutical Co., Ltd. - Preclinical, 2014 15
Taisho Pharmaceutical Co., Ltd. - Discovery, 2014 16
Taisho Pharmaceutical Co., Ltd. - Unknown, 2014 17
Taisho Pharmaceutical Co., Ltd. - Pipeline by Target, 2014 30
Taisho Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2014 31
Taisho Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2014 32
Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 33
Taisho Pharmaceutical Co., Ltd. - Recent Pipeline Updates, 2014 34
Taisho Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2014 35
Taisho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2014 36
Taisho Pharmaceutical Co., Ltd., Other Locations 37
Taisho Pharmaceutical Co., Ltd., Subsidiaries 38

List of Figures

Taisho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2014 7
Taisho Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2014 9
Taisho Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2014 10
Taisho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2014 29
Taisho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014 31
Taisho Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014 32
Taisho Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2016’, provides in depth analysis ...

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

5% Nucleotidase (Ecto 5% Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘5' Nucleotidase (Ecto 5' Nucleotidase or CD73 or NT5E or EC 3.1.3.5) ...

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • December 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 2 (Neuroblastoma Specific Potassium Channel Subunit Alpha KvLQT2 or Voltage Gated Potassium Channel Subunit Kv7.2 or KCNQ2) - Pipeline Review, H2 2016 ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.